NASDAQ · XBIT
XBiotech Inc.
$2.27 -$0.01 (-0.44%) 1D Market openKey Metrics
$69.51M
Market cap
12.92×
P/E · TTM
—
Revenue · TTM
$5.38M
Net income
EPS · TTM
$0.18
Dividend yield
—
Free cash flow
—
Beta · 1Y
0.63
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$69.51M
Enterprise value—
Shares outstanding30.5M
52-wk range$2.09 – $3.61
Avg volume · 20D67.5K
Net cash
—
Book value / share$4.43
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About XBiotech Inc.
IPO dateApr 15, 2015
Employees87
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E12.92
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №$4.19
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
4.0% · —
Financial Health
Current ratio39.03
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital$114.05M
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
0 / 9
Weak fundamentals · 0 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
$4.19 vs $2.27
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings